



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61F 2/00, A61L 31/00	A1	(11) International Publication Number: WO 99/51163 (43) International Publication Date: 14 October 1999 (14.10.99)
(21) International Application Number: PCT/EP99/02199 (22) International Filing Date: 31 March 1999 (31.03.99) (30) Priority Data: 09/054,672 3 April 1998 (03.04.98) US (71) Applicant: BIONX IMPLANTS OY [FI/FI]; Hermiankatu 6-8 L, FIN-33720 Tampere (FI). (72) Inventors: TÖRMÄLÄ, Pertti; Nestori Sarrinkatu 1, FIN-33720 Tampere (FI). PAASIMAA, Senja; Lindforsinkatu 6 C 42, FIN-33720 Tampere (FI). ANTIKAINEN, Teuvo; Kariniementie J6, FIN-40520 Jyväskylä (FI). (74) Agent: KEIL & SCHAAFHAUSEN; Cronstettenstrasse 66, D-60322 Frankfurt am Main (DE).		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HERNIA MESH (57) Abstract According to the present invention, a flexible, fibrous hernia mesh is provided, which is intended to be implanted to close hernia defects. The mesh has at least two functional components or layers: (1) a rapidly degradable first layer and (2) a more slowly degradable (with respect to the first layer) second layer. Using the fibrous mesh of this invention, the hernia defect can be closed so that a) the second layer supports the area until the scar tissue is strong enough (around 6 months), to prevent recurrent hernia formation, b) while the more rapid degradation of the first layer induces scar tissue formation due to inflammatory reaction, and c) the second layer isolates the first layer from the abdominal cavity, preventing tissue to tissue adhesion onto the intestines. The mesh is placed on the uncovered fascia area with its more rapidly absorbable side (the first layer) towards the fascia.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HERNIA MESH

FIELD OF THE INVENTION

The present invention relates to a biologically active hernia mesh, and methods of its
5 manufacture.

BACKGROUND OF THE INVENTION

Traditionally, a hernia bulging through any region of the abdominal wall would be repaired by an open hernioplasty and based on a method where the hernia defect becomes
10 closed and reinforced by adjacent tissues. In cases of very large or recurrent hernias, meshes of some nonabsorbable synthetic material have been used for repair. During a period of 3 to 6 months following the hernia operation, the repaired site gradually gathers scar tissue which builds up to strengthen the region.

Recurrent hernias are a common problem in hernia surgery. Even the best reports
15 indicate from 1% to 4% recurrent hernias after primary surgery, and some authors report figures up to 20%. These figures are much lower when a non-absorbable mesh is utilized in the method of repair.

The new trends for hernia repair include mini-invasive techniques, in which the hernia defect is closed by a piece of non-absorbable mesh with minimal tension. The follow-up
20 times thus far are short for such procedures, but it seems that recurrence rates of 1% or below could be expected. Also, the general recovery time has become shorter, and the patients are usually encouraged to begin their normal activities with no restrictions within a week after the operation.

The commercially available meshes used in hernia repair today are typically made of various plastics. They are known to stay biostable and safe at least for the usual follow-up time of 5 to 10 years after implantation. However, many hernia patients are young people with expected lifespans of decades. Nothing is known about the fate of, or tissue reactions possibly awakened by, the relatively massive plastic meshes after implantation and passage of some decades. Permanent surgical implants (metals, plastics, silicone, etc.) have been shown to cause side effects in many patients because of corrosion, wearing, migration, chronic inflammation and risk of infection. When the foreign material is placed near sensitive organs, the risks of these side effects can be severe to the patient's well being. In the case of hernia surgery, the plastic mesh will always become situated into close contact with the sensitive intra-abdominal organs.

Bioabsorbable meshes made of polyglycolic acid and its lactide copolymer (e.g., DEXON™, available from Davis & Geck, USA; and VICRYL™, available from Ethicon, Johnson & Johnson, U.S.A., are also known. Since the 1970's, these same materials have been used in surgery as sutures. No major harm to the tissues has been generally reported from use of these materials, and these materials also induce fibrogenesis and scar formation to some extent. Unfortunately, sutures and meshes manufactured of polyglycolic acid or its lactide copolymers (with around 10 mol-% of lactide units) tend to lose their strength within about 1 month after implantation, in which time the hernia site would not have enough time to heal and form scar tissue to resist pressure.

SUMMARY OF THE INVENTION

According to the present invention, a flexible, fibrous hernia mesh is provided, which is intended to be implanted to close hernia defects. The mesh has at least two functional components or layers: (1) a rapidly degradable first layer and (2) a more slowly degradable (with respect to the first layer) second layer. Using the fibrous mesh of this invention, the hernia defect can be closed so that a) the second layer supports the area until the scar tissue is strong enough (around 6 months), to prevent recurrent hernia formation, b) while the more rapid degradation of the first layer induces scar tissue formation due to inflammatory reaction, and c) the second layer isolates the first layer from the abdominal cavity, preventing tissue to tissue adhesion onto the intestines. The mesh is placed on the uncovered fascia area with its more rapidly absorbable side (the first layer) towards the fascia.

DETAILED DESCRIPTION OF THE EMBODIMENTS

The present invention relates to an implant, for hernia defect closure, for supporting the formation of scar tissue after implantation and for preventing tissue to tissue adhesion at the same time in the hernioplasty.

In this invention, it has been found out that using a porous, flexible, and fibrous mesh having at least two layers: (1) a more rapidly degradable first layer and (2) a more slowly degradable (with respect to the first layer) second layer, the above mentioned disadvantages of the prior art implants can be largely reduced or avoided, and the methods used for hernioplasty can be improved, particularly to enhance the formation of scar tissue and to avoid any possible long term foreign-body reactions. The hernia mesh of this invention is

made from bioabsorbable polymers, copolymers, polymer blends or by combining various bioabsorbable polymer parts.

Using the fibrous mesh of this invention, the hernia defect can be closed so that a) the more slowly degrading (with respect to the first layer) second layer supports the hernia area until the scar tissue is strong enough to prevent recurrent hernia formation (appr. 6 months), b) scar tissue formation is enhanced due to the inflammatory reaction caused by the more rapid degradation of the first layer, and c) tissue to tissue adhesion onto the intestines is prevented. The mesh of the invention is placed on the uncovered fascia area with its more quickly absorbable side towards the fascia. The mesh is fixed with bioabsorbable sutures or clips.

The mesh of the invention when implanted, for example, through a laparoscope, will typically induce strong fibrotic scar tissue formation on the more rapidly degrading first layer of the mesh soon after the operation, due to the porous structure and quick degradation of the first layer. The functions of the second layer are to support the hernia area until the scar tissue is strong enough to resist pressure and to prevent tissue to tissue adhesion onto the intestines. To further improve the tissue to tissue adhesion preventing effect of the mesh, a third layer, a film, can be included as part of the structure of the mesh. The third layer prevents inflammatory agents, which could cause tissue to tissue adhesion, from moving from the hernia area through the mesh and onto the surrounding tissues.

The mesh of the invention acts as a temporary support until the connective scar tissue has strengthened enough and can replace the mesh, when the second layer finally degrades. At that point, the hernia defect closure is then finally formed entirely of the patient's own tissue, following absorption of the whole synthetic mesh. Compared to the so-called

biostable meshes, no wear debris will come loose from the bioabsorbable material of the present invention on a long term (e.g., 5 years after operation or later) basis, thereby eliminating risks for long term foreign-body complications or chronic inflammatory reactions.

5 The mesh according to this invention can be produced of fibers made of bioabsorbable polymer, copolymer, polymer blend or polymer composite, or by combining different bioabsorbable polymer parts. In medical, technical and patent literature there have been presented many polymers, which can be used as a raw material for the fibers of the hernia mesh of this invention. There are, for example, bioabsorbable aliphatic polyesters.

10 polyanhydrides, poly (ortho esters) polymers, which are presented, for example, in FI Pat. Apl 952884 and PCT application PCT/FI96/00351 "Nivelproteesi", the disclosures of which are incorporated herein by reference.

 The first layer of the mesh according to this invention is porous, with the optimal pore size being between 50 μm - 1000 μm . Utilizing this optimal pore size enables the connective

15 tissue cells to grow into the porosity of the mesh after implantation, and strengthens formation of the scar tissue.

 The second layer of the mesh according to this invention can be dense or porous, or a combination of both. If the second layer is porous, the optimal pore size is around 0.1 mm to 2.0 mm, in order to maximize the supporting effect of the second layer. However, the second

20 layer is also soft and flexible, in order that the operation can still be accomplished through a laparoscope.

 The optional third layer of the mesh according to this invention is a dense, thin, bioabsorbable film, which prevents agents that could cause tissue to tissue adhesion from

moving from the hernia area through the mesh and onto the surrounding tissue, during the first weeks after the operation. The third layer film also acts as a support layer immediately after the operation. The thickness of the bioabsorbable film is optimally between 1-300 μm . The third layer is also soft and flexible in order that the operation through a laparoscope is still possible.

A porous structure is most easily imbued in the mesh of this invention by making the mesh from fibers and using known textile processing methods, for example, knitting, weaving and non-woven manufacturing methods. Also, any other processing methods that result in porous structures can be used to make the mesh of this invention.

Different drugs and/or growth factors can be added into the mesh structure of the invention, to improve the functionality of the implant. Angiogenetic growth factors can be used to accelerate the growth of connective tissue. Also, for example, cyclosporine can be used in the structure to prevent, more effectively, tissue to tissue adhesion of the mesh onto the intestines

The functionality of this invention is further described in the following non-restrictive examples.

Example 1.

The hernia mesh was made of commercial polyglycolide (PGA) biosbsorbable DEXON MESH™ (available from Davis & Geck, USA) and more slowly degradable poly (L/D lactide), [P (L/D)LA, monomer ratio 96/4, I.V. = 6.8 dl/g, producer Purac Biochem, The Netherlands]].

Fibers were melt-spun with a one screw extruder (Axon, Sweden), and the polymer melt (at $T=200-270^{\circ}\text{C}$) was pressed through four round die holes having a diameter of 0.4 mm. After cooling to room temperature, the filaments were oriented freely in a two step process at elevated temperature ($60-140^{\circ}\text{C}$). The draw ratio was 4-8. The final filament diameter was $50\text{ }\mu\text{m}$

The filaments were then knitted by using a warp knitting machine, the fabric having a loop size of about 1 mm. The knitted fabric was combined with the DEXON MESH™ by sewing. The dimensions of this fibrous two-layer composite mesh were 25 cm x 15 cm. The meshes were sterilized with ethylene oxide gas.

Example 2.

The hernia mesh was made using two different polymers as raw materials: the copolymer of L lactic acid and and glycolide (P(L/GA)), monomer ratio 10/90, i.v. 1.58 dl/g, producer Purac Biochem b.v., The Netherlands) and poly L/D lactide (monomer ratio L/D 96/4, i.v. 6.8 dl/g, producer Purac Biochem b.v., The Netherlands). The fibers were spun as in Example 1. The multifilament yarns were knitted into a form of hybrid fabric having a mesh like structure. The mesh was sterilized with ethylene oxide gas.

Example 3.

The hernia mesh was made of the commercial bioabsorbable PGA DEXON MESH™, style 4, and copolymer of L-lactic acid and ϵ -caprolactone, P(L-LA/E-CL) available from the Helsinki University of Technology ("HUT"), Finland, having a monomer ratio of 10/90 and $M_w = 260,000$ dalton.

Biaxially oriented P(L-LA/E -CL) film having thickness of 20 μ m was made using an extrusion process. The film and the DEXON MESH™ were fixed together by sewing. The final composite mesh had dimensions of 12 x 10 cm. The meshes were sterilized with ethylene oxide gas.

5

Example 4.

Laparoscopic hernioplasty

The patient was in general anesthesia and laying supine in an 20 degree Trendelenburg's position. The abdominal cavity was penetrated by a needle and insufflated up to 10 mmHg using carbondioxide gas. Three troacars (10/12 mm) are thus placed: the first near the umbilicus and the other two some centimeters below on each side. The hernial sac (peritoneum) was grasped and pulled from the hernial defect. The sac was then opened by beginning the dissection laterally from the inner inguinal canal and advancing medially 3 cm across the edge of the rectus muscle. Thus, the flap of peritoneum was created under which the fascia of transversus abdominis was seen. A tightly rolled 8x10 cm composite mesh according to Example 1 was introduced into the abdominal cavity, unrolled and placed on the uncovered fascia area with its more quickly absorbable (PGA) side towards the fascia. The peritoneal flap was then placed over the mesh and both were fixed onto the underlaying fascia with 5 to 10 titanium staples. Sometimes it is difficult to hide all parts of the mesh, but in case of the absorbable composite mesh this does not matter, because the smooth and slowly resorbable P(L/D)LA fiber surface of the mesh will not give rise to intra-abdominal adhesions or irritation. The operation was terminated by desufflating the abdominal cavity, pulling out the trocars and suturing the three 1 cm wounds.

The patient was encouraged to take part in his normal activities after a sick leave of one week.

The hernial defect is closed by a scar plate within 3 to 6 months, in which time the absorbable mesh composite will gradually lose its strength and consistency. In the end, no permanent foreign material will be left when both fibrous components of the mesh have bioabsorbed in around 3-4 years.

Example 5.

Lichtenstein's hernioplasty (male patient): The patient lays supine. Some 10 to 20 ml of local anesthetic was applied at the inguinal region. An incision measuring 7 cm was positioned along the inguinal ligament and at the level of pubic symphysis. The roof of the inguinal canal was then incised and the spermatic cord detached from its attachments. This reveals the hernial sac and allows the surgeon to invert it back to the abdominal cavity. The inguinal ligament and the lateral border of the rectus abdominis muscle were then exposed. The absorbable mesh composite (size 7.5 cm x 15 cm) according to Example 1 is then sutured to these structures. The mesh should now cover the entire inguinal canal allowing only the funicle to pass through. Care must be taken to place the mesh to face its more slowly resorbable side downwards. The roof of the inguinal canal was then reconstructed using resorbable sutures and the skin was closed by sutures or staples. The patient may leave the hospital after some hours. The usual sick leave time is 1 to 2 weeks, after which all daily activities are allowed. The trauma caused by the dissection and the inflammation aroused by the mesh composite will induce fibroplasia to form a scar which, in 3 to 6 months, will

support the bottom of the inguinal canal and prevent recurrent hernia formation. No permanent foreign material is left in the patient.

We claim:

1. A hernia mesh for use in repairing a defect in an abdominal wall or cavity, said mesh comprising:
 - a first layer capable of being anchored on the abdominal wall next to the defect, wherein said first layer has a first degradation time and is made from a bioabsorbable polymer, copolymer, polymer blend or polymer composite, and
 - a second layer, wherein said second layer is configured such that it is fixed on the first layer and capable of being placed in contact with the abdominal wall or cavity, wherein said second layer has a second degradation time that is longer than the first degradation time, and the second layer is made from bioabsorbable polymer, copolymer, polymer blend or polymer composite.
2. A mesh as set forth in claim 1, wherein said first layer has a fibrous structure made of woven fabric, knitted fabric, mesh or non-woven felt, made of filaments or staple fibers.
3. A mesh as set forth in claim 2, wherein said second layer is made of film or woven fabric, knitted fabric, mesh or non-woven felt, made of filaments or staple fibers.
4. A mesh as set forth in claims 3, further comprising a third layer comprising a biodegradable film, said third layer being positioned between the first layer and the second layer.

5. A mesh as set forth in claims 4, wherein the mesh is plane like.
6. A mesh as set forth in claims 5, wherein the first layer is porous and has a pore size between 50 - 1000 μm .
7. A mesh as set forth in claims 6, wherein the mesh is made of biodegradable fibers having fiber diameter of 1-300 μm .

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02199

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61F2/00 A61L31/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61F A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 222 954 A (ETHICON INC) 28 March 1990 (1990-03-28) abstract; claims; figures; example 4	1-3
A	---	4-7
A	US 5 686 090 A (DAHLKE HERMANN ET AL) 11 November 1997 (1997-11-11) column 1, line 30 - column 2, line 48; figures	1-5
A	---	
A	EP 0 797 962 A (ETHICON GMBH) 1 October 1997 (1997-10-01) page 2, line 25 - line 45; figures	1-3
A	---	
A	WO 96 31157 A (ORGANOGENESIS INC ; TERMIN PAUL L (US); CARR ROBERT M JR (US); COND) 10 October 1996 (1996-10-10) claims 1-18; examples 5-7	1-3

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 August 1999

Date of mailing of the international search report

16/08/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Neumann, E

INTERNATIONAL SEARCH REPORT

Inte. .dional Application No

PCT/EP 99/02199

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DE 36 19 197 A (ETHICON GMBH) 10 December 1987 (1987-12-10) column 3, line 59 - column 4, line 5; claims 1,3-5</p> <p>-----</p>	1-3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02199

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2222954 A	28-03-1990	DE 3830005 C	02-11-1989
		DE 3830481 A	22-03-1990
		JP 2167156 A	27-06-1990
		JP 2763801 B	11-06-1998
		FR 2635966 A	09-03-1990
US 5686090 A	11-11-1997	AU 666600 B	15-02-1996
		AU 5477194 A	04-08-1994
		BR 9400359 A	16-08-1994
		CA 2114282 A	29-07-1994
		GR 1002613 B	20-02-1997
		JP 7047090 A	21-02-1995
EP 0797962 A	01-10-1997	DE 19613730 A	02-10-1997
		AU 704334 B	22-04-1999
		AU 1648597 A	02-10-1997
		BR 9701466 A	10-11-1998
		CA 2200801 A	26-09-1997
		JP 10024054 A	27-01-1998
		ZA 9702563 A	25-09-1998
WO 9631157 A	10-10-1996	US 5733337 A	31-03-1998
		AU 5308396 A	23-10-1996
		CA 2217581 A	10-10-1996
		EP 0828453 A	18-03-1998
		JP 11503051 T	23-03-1999
DE 3619197 A	10-12-1987	AU 619445 B	30-01-1992
		AU 7385587 A	10-12-1987
		BR 8702875 A	01-03-1988
		CA 1317836 A	18-05-1993
		DE 3781958 A	05-11-1992
		EP 0252607 A	13-01-1988
		JP 2567400 B	25-12-1996
		JP 63046151 A	27-02-1988
		US 4796603 A	10-01-1989